

MPH Health Care AG

Germany / Healthcare
 Frankfurt
 Bloomberg: 93M1 GR
 ISIN: DE000A289V03

2020
 Prelims

RATING
BUY

PRICE TARGET
€ 75.00

Return Potential 173.7%
 Risk Rating High

RESULTS DOWN ON WEAK M1 STOCK PERFORMANCE

Prelims reflect covid-19 effects with 2020 net income sinking to €70m (2019: €11m). This owes to non-cash fair value write-downs of the listed holdings. The weak result is chiefly traced to the poor M1 stock performance last year (-35%) in the wake of pandemic lockdowns. M1 earnings were burdened by clinic closures and restrictions limiting the number of treatments last year. However, there is no evidence of long-term effects on operations or the capital structure, and we see good rebound potential once the covid-19 tentacles retreat from global economies. Meanwhile, CR Capital remains unhampered by the pandemic as the property developer continues to address frenzied demand for affordable housing. Our rating remains Buy with an unchanged €75 price target.

What happened with M1? M1 prelims were slightly below street forecasts with 2020 EPS declining to €0.37 vs €0.56 in the prior year as the beauty treatment business was held back by pandemic countermeasures. M1 shut down its clinics and practices in March 2020 in compliance with the nationwide lockdowns. These re-opened in May and business immediately hit pre-lockdown levels. However, further restrictions at home and renewed lockdowns abroad in Q4 gated the number of treatments performed. M1 recently confirmed plans to expand and further internationalise its clinic network to 100 aesthetic medicine centres by 2024 and targets 50 facilities by YE21. Management will propose to the AGM that 2020 profits be fully retained to finance this envisioned growth.

Upshot for the beauty and lifestyle specialist Last year was about weathering the pandemic storm. We think M1 was able to absorb the earnings shortfall without severe long-term effects on its balance sheet—the YE20 equity ratio was 61%. Although renewed lockdowns will burden H1/21 performance, we see good catch-up potential on the other side of covid-19 restrictions. Pent-up demand is evidenced by the 20% Y/Y jump in Q3/20 injection and surgical treatments performed in Germany, when the number hit 65K for. . . (p.t.o.)

FINANCIAL HISTORY & PROJECTIONS

	2017	2018	2019	2020E	2021E	2022E
Pro-forma rev. (€m) ¹	57.60	91.52	117.73	212.58	392.05	472.34
Y/Y growth	7.8%	58.9%	28.6%	80.6%	84.4%	20.5%
Operating revenue (€m)	34.24	39.53	41.22	1.89	37.74	27.31
EBIT (€m)	32.30	37.64	11.6	-21.99	32.05	21.50
Net income (€m)	31.86	37.03	11.08	-70.31	30.88	20.53
EPS (diluted) (€)	7.44	8.65	2.59	-16.42	7.21	4.80
DPS (€)	2.00	2.00	0.00	0.00	1.50	1.58
NAVPS (€)	56.22	62.87	63.45	47.03	54.24	57.53
Net gearing	2.4%	4.8%	6.1%	6.5%	1.7%	0.3%
Liquid assets (€m)	8.29	1.08	2.10	1.82	11.10	14.15

¹ We provide pro-forma revenue of M1 Kliniken and CR Capital as a reference.

RISKS

Regulatory changes in healthcare systems, homogenization of pharmaceutical prices within the EU, and prolonged macro economic downturns that limit private healthcare spend.

COMPANY PROFILE

MPH Health Care AG is a Berlin-based investment company focused on the purchase and further development of companies positioned chiefly in growth segments of the healthcare market. These primarily entail specialty pharmaceuticals for chronic diseases and lifestyle and beauty treatments. The company also holds a stake in a residential property developer.

MARKET DATA

As of 05 May 2021

Closing Price	€ 27.40
Shares outstanding	4.28m
Market Capitalisation	€ 117.30m
52-week Range	€ 18.66 / 32.10
Avg. Volume (12 Months)	2,862

Multiples	2019	2020E	2021E
P/E	10.6	n.a.	3.8
EV/EBIT	11.1	n.a.	4.0
P/NAV	0.4	0.6	0.5
Div. Yield	0.0%	0.0%	5.5%

STOCK OVERVIEW



COMPANY DATA

As of 30 Jun 2020

Liquid Assets	€ 0.40m
Current Assets	€ 2.44m
Financial Assets	€ 250.84m
Total Assets	€ 253.33m
Current Liabilities	€ 9.09m
Shareholders' Equity	€ 238.99m

SHAREHOLDERS

Magnum	60.0%
Baring Fund Managers	1.7%
KBC Asset Management SA	1.3%
Free Float	37.0%



. . . the quarter after restrictions eased. We expect similar catch-up effects once the pandemic runs its course. Moreover, M1's re-homed product business (see note of 30 June 2020) is now spearheaded by HAEMATO, which M1 now fully consolidates (69% stake). In our view, this is a much better operational and strategic fit to exploit opportunities for own-branded products. We reckon these factors are a good basis for a rebound in the M1 share price, which continues to trade some 36% off pre-pandemic levels.

HAEMATO is now also a pandemic play HAEMATO's fully owned subsidiary, HAEMATO PHARM GmbH, recently received special approval from the Federal Institute for Drugs and Medical Devices (BfArM) according to § 11 Para.1 to supply self-antigen rapid tests. The company has secured flexible supply of up to 200m of its self-test kits to sell into the pharmacy, wholesale, and public institution channels. With covid-19 lockdowns still in fashion, this looks like an attractive segment and equates to a good pandemic hedge for investors. Early traction shows ~€25m in sales are being realised in the first half of April.

We also emphasize that antigen-test upside is not factored into HAEMATO's 2021 guidance. Depending on how the pandemic plays out, this segment could result in a windfall profit giving the specialty-pharmaceutical vendor excellent financial flexibility to execute on the full pipeline of its core business and / or reward investors with a special dividend.

CR CAPITAL CONTINUES TO BENEFIT FROM THE SUBURBAN SHUFFLE

The company exited 2020 largely unscathed by the pandemic. February prelims featured €45m in net profit alongside NAVPS of €42 and a 90% equity ratio.

We like CR Capital for its position in the residential property segment. The company specialises in the construction of affordable housing predominantly in Leipzig, Berlin, and the Berlin exurbs and is benefiting from a residential market that continues to be shaped by an acute housing shortage, particularly for affordable homes, and soaring rents. Plus, owning a town house or flat has rarely been so attractive, thanks to rock bottom mortgage lending rates (~0.75%) coupled with an €18k KfW loan credit and another €12k child benefit subsidy.

After beefing up its staff last year with key personnel, we think development capacity stands at roughly 200 units per annum. Plus, according to the February announcement, management have locked down contractors for the next three years to execute on a full pipeline with > 600 units under development. CR Capital will publish its annual report and propose a dividend in July.



VALUATION

NAVPS declined 26% on an annualised basis to €47.0 vs €63.5 at YE19 and €45.4 at the 9M/20 mark. Management will propose to this year's AGM not to distribute a dividend, given current market uncertainties.

We use a sum-of-the-parts valuation methodology to value MPH. Value is driven by the projected fair value of M1 Kliniken and CR Capital, which we have valued separately on a DCF basis. Shareholdings reflect H1/20 reporting. We will update the listed portfolio stakes on publication of the annual report at the end of May. We remain Buy-rated on MPH with an unchanged €75 price target.

Table 1: Sum-of-the-parts model

Unit	Shareholdings '000	SO '000	MPH stake %	Share price* €	Fair value per share ¹ €	Projected value €m
M1 Kliniken AG	13,155	19,643	67%	10.5	20.5	270
CR Capital Real Estate AG	2,150	3,756	57%	31.3	37.0	80
Projected value of listed holdings						349

* Source: Bloomberg (Previous day's closing price)

	Unit	Value
Fair value of listed portfolio	€m	349
Non-listed investment (book value)	€m	27
Net debt	€m	16
Present value of holding costs	€m	-39
Total fair value	€m	320
MPH shares outstanding	m	4
Fair value per share	€	75

¹ First Berlin Equity Research covers CR Capital (Buy / PT: €37); M1 fair value is based on a DCF



INCOME STATEMENT

All figures in EUR '000	2017	2018	2019	2020E	2021E	2022E
Pro-forma revenues¹	57,604	91,517	117,732	212,581	392,051	472,342
Fair value gains on financial assets	25,583	31,019	33,747	0	27,100	16,563
Income from participations	848	170	780	350	400	400
Investment income	7,380	8,317	6,651	1,500	10,199	10,302
Other operating income	425	28	43	43	45	47
Operating revenue	34,236	39,534	41,221	1,893	37,744	27,312
SG&A	-1,177	-1,146	-934	-981	-1,030	-1,081
Other OpEx	-360	-703	-1,494	-1,569	-1,647	-1,729
Fair value loss on financial assets	-392	0	-27,207	-70,600	-3,000	-3,000
Depreciation & amortisation	-21	-45	-11	0	-20	-12
EBIT	32,286	37,640	11,575	-71,256	32,047	21,488
Interest expense	-499	-507	-540	-540	-540	-540
Interest income	332	209	15	55	0	0
EBT	32,119	37,342	11,050	-71,741	31,507	20,948
Income taxes	-264	-317	27	1,435	-630	-419
Net income / loss	31,855	37,025	11,076	-70,307	30,877	20,530
Minority interests	0	0	0	0	0	0
Net income after minorities	31,855	37,025	11,076	-70,307	30,877	20,530
EPS (in €)	7.44	8.65	2.59	-16.42	7.21	4.80

¹Pro-forma revenue of M1 Kliniken and CR Capital as a reference.



BALANCE SHEET

All figures in EUR '000	2017	2018	2019	2020E	2021E	2022E
Assets						
Current assets, total	8,288	1,152	2,237	1,970	11,264	14,327
Cash and equivalents	1,239	1,018	1,797	1,511	10,784	13,825
ST financial assets	7,046	64	305	311	317	324
Trade receivables	0	3	4	4	4	4
Inventories	0	7	0	0	0	0
Other ST assets	3	60	131	144	159	174
Non-current assets, total	249,069	285,101	290,908	217,308	238,909	249,973
Property, plant & equipment	4	2	56	56	57	58
Goodwill & other intangibles	18	1	1	1	1	1
Financial assets	249,047	285,098	290,851	217,251	238,851	249,914
Total assets	257,357	286,253	293,144	219,278	250,173	264,300
Shareholders' equity & debt						
Current liabilities, total	229	327	15,724	150	155	159
Trade payables	37	28	24	24	24	24
Provisions	70	99	91	94	97	99
Other ST financial liabilities	90	87	15,578	0	0	0
Other current liabilities	32	113	31	33	34	36
Long-term liabilities, total	16,483	16,798	5,779	17,793	17,807	17,821
Long-term debt	14,000	14,000	3,000	15,000	15,000	15,000
Deferred tax liabilities & others	2,483	2,798	2,779	2,793	2,807	2,821
Shareholders' equity	240,665	269,127	271,641	201,335	232,212	246,319
Minority interests	0	0	0	0	0	0
Total equity	240,665	269,128	271,641	201,335	232,212	246,319
Total consolidated equity and debt	257,377	286,253	293,144	219,278	250,173	264,300
NAV	240,665	269,128	271,641	201,335	232,212	246,319
NAVPS (€)	56.2	62.9	63.5	47.0	54.2	57.5



CASH FLOW STATEMENT

All figures in EUR '000	2017	2018	2019	2020E	2021E	2022E
Net income	31,855	37,025	11,076	-70,307	30,877	20,530
Depreciation and amortisation	21	45	11	0	20	12
Revaluation gains	-25,946	-30,360	-6,540	70,594	-24,107	-13,569
Changes in working capital	2,485	7,058	-93	5	4	3
Other adjustments	-457	-830	384	0	0	0
Net financial result	167	299	526	485	540	540
Tax expense	264	317	-26	-1,435	630	419
Operating cash flow	8,389	13,554	5,337	-657	7,965	7,935
Investment income	-7,380	-8,317	-6,651	-1,500	-10,199	-10,302
Tax paid	0	-41	-38	1,435	-630	-419
Net operating cash flow	1,009	5,196	-1,352	-723	-2,864	-2,786
CapEx	-11	-11	-52	0	-22	-13
Payments from acquisitions of consolidated companies & other business units	-15,978	0	1,856	0	0	0
Proceeds from disposal of fixed assets	13,160	11,783	17,661	3,000	2,500	2,500
Payments for investment in financial assets	0	-16,644	-19,116	0	0	0
Investment income	7,380	8,317	6,378	1,500	10,199	10,302
Interest income	332	208	15	55	0	0
Cash flow from investing	4,883	3,653	6,742	4,555	12,677	12,788
Equity inflow, net	0	0	-1	0	0	0
Debt inflow, net	0	0	4,492	-3,578	0	0
Dividend paid to shareholders	-5,137	-8,563	-8,562	0	0	-6,422
Interest expense	-499	-507	-540	-540	-540	-540
Cash flow from financing	-5,636	-9,070	-4,611	-4,118	-540	-6,962
Net cash flows	256	-221	779	-286	9,273	3,040
Cash, start of the year	983	1,239	1,018	1,797	1,511	10,784
Cash, end of the year	1,239	1,018	1,797	1,511	10,784	13,825
Free cash flow (FCF)	5,892	8,849	5,390	3,832	9,813	10,002
Y-Y Growth						
Operating cash flow	n.a.	415.0%	n.m.	n.m.	n.m.	n.m.
Free cash flow	n.a.	50.2%	-39.1%	-28.9%	156.1%	1.9%

Imprint / Disclaimer

First Berlin Equity Research

First Berlin Equity Research GmbH ist ein von der BaFin betreffend die Einhaltung der Pflichten des §85 Abs. 1 S. 1 WpHG, des Art. 20 Abs. 1 Marktmissbrauchsverordnung (MAR) und der Markets Financial Instruments Directive (MiFID) II, Markets in Financial Instruments Directive (MiFID) II Durchführungsverordnung und der Markets in Financial Instruments Regulations (MiFIR) beaufsichtigtes Unternehmen.

First Berlin Equity Research GmbH is one of the companies monitored by BaFin with regard to its compliance with the requirements of Section 85 (1) sentence 1 of the German Securities Trading Act [WpHG], art. 20 (1) Market Abuse Regulation (MAR) and Markets in Financial Instruments Directive (MiFID) II, Markets in Financial Instruments Directive (MiFID) II Commission Delegated Regulation and Markets in Financial Instruments Regulations (MiFIR).

Anschrift:

First Berlin Equity Research GmbH
 Mohrenstr. 34
 10117 Berlin
 Germany

Vertreten durch den Geschäftsführer: Martin Bailey

Telefon: +49 (0) 30-80 93 9 680

Fax: +49 (0) 30-80 93 9 687

E-Mail: info@firstberlin.com

Amtsgericht Berlin Charlottenburg HR B 103329 B

UST-Id.: 251601797

Ggf. Inhaltlich Verantwortlicher gem. § 6 MDStV

First Berlin Equity Research GmbH

Authored by: Ellis Acklin, Senior Analyst

All publications of the last 12 months were authored by Ellis Acklin.

Company responsible for preparation: First Berlin Equity Research GmbH, Mohrenstraße 34, 10117 Berlin

The production of this recommendation was completed on 6 May 2021 at 11:30

Person responsible for forwarding or distributing this financial analysis: Martin Bailey

Copyright© 2021 First Berlin Equity Research GmbH No part of this financial analysis may be copied, photocopied, duplicated or distributed in any form or media whatsoever without prior written permission from First Berlin Equity Research GmbH. First Berlin Equity Research GmbH shall be identified as the source in the case of quotations. Further information is available on request.

INFORMATION PURSUANT TO SECTION 85 (1) SENTENCE 1 OF THE GERMAN SECURITIES TRADING ACT [WPHG], TO ART. 20 (1) OF REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF APRIL 16, 2014, ON MARKET ABUSE (MARKET ABUSE REGULATION) AND TO ART. 37 OF COMMISSION DELEGATED REGULATION (EU) NO 2017/565 (MIFID) II.

First Berlin Equity Research GmbH (hereinafter referred to as: "First Berlin") prepares financial analyses while taking the relevant regulatory provisions, in particular section 85 (1) sentence 1 of the German Securities Trading Act [WpHG], art. 20 (1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) and art. 37 of Commission Delegated Regulation (EU) no. 2017/565 (MiFID II) into consideration. In the following First Berlin provides investors with information about the statutory provisions that are to be observed in the preparation of financial analyses.

CONFLICTS OF INTEREST

In accordance with art. 37 (1) of Commission Delegated Regulation (EU) no. 2017/565 (MiFID) II and art. 20 (1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) investment firms which produce, or arrange for the production of, investment research that is intended or likely to be subsequently disseminated to clients of the firm or to the public, under their own responsibility or that of a member of their group, shall ensure the implementation of all the measures set forth in accordance with Article 34 (2) lit. (b) of Regulation (EU) 2017/565 in relation to the financial analysts involved in the production of the investment research and other relevant persons whose responsibilities or business interests may conflict with the interests of the persons to whom the investment research is disseminated. In accordance with art. 34 (3) of Regulation (EU) 2017/565 the procedures and measures referred to in paragraph 2 lit. (b) of such article shall be designed to ensure that relevant persons engaged in different business activities involving a conflict of interests carry on those activities at a level of independence appropriate to the size and activities of the investment firm and of the group to which it belongs, and to the risk of damage to the interests of clients.

In addition, First Berlin shall pursuant to Article 5 of the Commission Delegated Regulation (EU) 2016/958 disclose in their recommendations all relationships and circumstances that may reasonably be expected to impair the objectivity of the financial analyses, including interests or conflicts of interest, on their part or on the part of any natural or legal person working for them under a contract, including a contract of employment, or otherwise, who was involved in producing financial analyses, concerning any financial instrument or the issuer to which the recommendation directly or indirectly relates.

With regard to the financial analyses of MPH Health Care AG the following relationships and circumstances exist which may reasonably be expected to impair the objectivity of the financial analyses: The author, First Berlin, or a company associated with First Berlin reached an agreement with the MPH Health Care AG for preparation of a financial analysis for which remuneration is owed.

Furthermore, First Berlin offers a range of services that go beyond the preparation of financial analyses. Although First Berlin strives to avoid conflicts of interest wherever possible, First Berlin may maintain the following relations with the analysed company, which in particular may constitute a potential conflict of interest:

- The author, First Berlin, or a company associated with First Berlin owns a net long or short position exceeding the threshold of 0,5 % of the total issued share capital of the analysed company;
- The author, First Berlin, or a company associated with First Berlin holds an interest of more than five percent in the share capital of the analysed company;

- The author, First Berlin, or a company associated with First Berlin provided investment banking or consulting services for the analysed company within the past twelve months for which remuneration was or was to be paid;
- The author, First Berlin, or a company associated with First Berlin reached an agreement with the analysed company for preparation of a financial analysis for which remuneration is owed;
- The author, First Berlin, or a company associated with First Berlin has other significant financial interests in the analysed company;

With regard to the financial analyses of MPH Health Care AG the following of the aforementioned potential conflicts of interests or the potential conflicts of interest mentioned in Article 6 paragraph 1 of the Commission Delegated Regulation (EU) 2016/958 exist: The author, First Berlin, or a company associated with First Berlin reached an agreement with the MPH Health Care AG for preparation of a financial analysis for which remuneration is owed.

In order to avoid and, if necessary, manage possible conflicts of interest both the author of the financial analysis and First Berlin shall be obliged to neither hold nor in any way trade the securities of the company analyzed. The remuneration of the author of the financial analysis stands in no direct or indirect connection with the recommendations or opinions represented in the financial analysis. Furthermore, the remuneration of the author of the financial analysis is neither coupled directly to financial transactions nor to stock exchange trading volume or asset management fees.

INFORMATION PURSUANT TO SECTION 64 OF THE GERMAN SECURITIES TRADING ACT [WPHG], DIRECTIVE 2014/65/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 15 MAY 2014 ON MARKETS IN FINANCIAL INSTRUMENTS AND AMENDING DIRECTIVE 2002/92/EC AND DIRECTIVE 2011/61/EU, ACCOMPANIED BY THE MARKETS IN FINANCIAL INSTRUMENTS REGULATION (MIFIR, REG. EU NO. 600/2014).

First Berlin notes that it has concluded a contract with the issuer to prepare financial analyses and is paid for that by the issuer. First Berlin makes the financial analysis simultaneously available for all interested security financial services companies. First Berlin thus believes that it fulfils the requirements of section 64 WpHG for minor non-monetary benefits.

PRICE TARGET DATES

Unless otherwise indicated, current prices refer to the closing prices of the previous trading day.

AGREEMENT WITH THE ANALYSED COMPANY AND MAINTENANCE OF OBJECTIVITY

The present financial analysis is based on the author's own knowledge and research. The author prepared this study without any direct or indirect influence exerted on the part of the analysed company. Parts of the financial analysis were possibly provided to the analysed company prior to publication in order to avoid inaccuracies in the representation of facts. However, no substantial changes were made at the request of the analysed company following any such provision.

ASSET VALUATION SYSTEM

First Berlin's system for asset valuation is divided into an asset recommendation and a risk assessment.

ASSET RECOMMENDATION

The recommendations determined in accordance with the share price trend anticipated by First Berlin in the respectively indicated investment period are as follows:

Category		1	2
Current market capitalisation (in €)		0 - 2 billion	> 2 billion
Strong Buy ¹	An expected favourable price trend of:	> 50%	> 30%
Buy	An expected favourable price trend of:	> 25%	> 15%
Add	An expected favourable price trend of:	0% to 25%	0% to 15%
Reduce	An expected negative price trend of:	0% to -15%	0% to -10%
Sell	An expected negative price trend of:	< -15%	< -10%

¹ The expected price trend is in combination with sizable confidence in the quality and forecast security of management.

Our recommendation system places each company into one of two market capitalisation categories. Category 1 companies have a market capitalisation of €0 – €2 billion, and Category 2 companies have a market capitalisation of > €2 billion. The expected return thresholds underlying our recommendation system are lower for Category 2 companies than for Category 1 companies. This reflects the generally lower level of risk associated with higher market capitalisation companies.

RISK ASSESSMENT

The First Berlin categories for risk assessment are low, average, high and speculative. They are determined by ten factors: Corporate governance, quality of earnings, management strength, balance sheet and financial risk, competitive position, standard of financial disclosure, regulatory and political uncertainty, strength of brandname, market capitalisation and free float. These risk factors are incorporated into the First Berlin valuation models and are thus included in the target prices. First Berlin customers may request the models.

RECOMMENDATION & PRICE TARGET HISTORY

Report No.:	Date of publication	Previous day closing price	Recommendation	Price target
Initial Report	29 October 2012	€24.55	Buy	€55.00
2...16	↓	↓	↓	↓
17	23 November 2017	€35.41	Buy	€69.00
18	13 June 2018	€50.63	Buy	€71.00
19	15 August 2019	€37.62	Buy	€75.00
20	30 June 2020	€27.94	Buy	€75.00
21	16 September 2020	€26.00	Buy	€75.00
22	7 December 2020	€22.20	Buy	€75.00
23	Today	€27.40	Buy	€75.00

INVESTMENT HORIZON

Unless otherwise stated in the financial analysis, the ratings refer to an investment period of twelve months.

UPDATES

At the time of publication of this financial analysis it is not certain whether, when and on what occasion an update will be provided. In general First Berlin strives to review the financial analysis for its topicality and, if required, to update it in a very timely manner in connection with the reporting obligations of the analysed company or on the occasion of ad hoc notifications.

SUBJECT TO CHANGE

The opinions contained in the financial analysis reflect the assessment of the author on the day of publication of the financial analysis. The author of the financial analysis reserves the right to change such opinion without prior notification.

Legally required information regarding

- **key sources of information in the preparation of this research report**
- **valuation methods and principles**
- **sensitivity of valuation parameters**

can be accessed through the following internet link: <https://firstberlin.com/disclaimer-english-link/>

SUPERVISORY AUTHORITY: Bundesanstalt für Finanzdienstleistungsaufsicht (German Federal Financial Supervisory Authority) [BaFin], Graurheindorferstraße 108, 53117 Bonn and Marie-Curie-Straße 24-28, 60439 Frankfurt am Main

EXCLUSION OF LIABILITY (DISCLAIMER)

RELIABILITY OF INFORMATION AND SOURCES OF INFORMATION

The information contained in this study is based on sources considered by the author to be reliable. Comprehensive verification of the accuracy and completeness of information and the reliability of sources of information has neither been carried out by the author nor by First Berlin. As a result no warranty of any kind whatsoever shall be assumed for the accuracy and completeness of information and the reliability of sources of information, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the accuracy and completeness of information and the reliability of sources of information.

RELIABILITY OF ESTIMATES AND FORECASTS

The author of the financial analysis made estimates and forecasts to the best of the author's knowledge. These estimates and forecasts reflect the author's personal opinion and judgement. The premises for estimates and forecasts as well as the author's perspective on such premises are subject to constant change. Expectations with regard to the future performance of a financial instrument are the result of a measurement at a single point in time and may change at any time. The result of a financial analysis always describes only one possible future development – the one that is most probable from the perspective of the author – of a number of possible future developments.

Any and all market values or target prices indicated for the company analysed in this financial analysis may not be achieved due to various risk factors, including but not limited to market volatility, sector volatility, the actions of the analysed company, economic climate, failure to achieve earnings and/or sales forecasts, unavailability of complete and precise information and/or a subsequently occurring event which affects the underlying assumptions of the author and/or other sources on which the author relies in this document. Past performance is not an indicator of future results; past values cannot be carried over into the future.

Consequently, no warranty of any kind whatsoever shall be assumed for the accuracy of estimates and forecasts, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the correctness of estimates and forecasts.

INFORMATION PURPOSES, NO RECOMMENDATION, SOLICITATION, NO OFFER FOR THE PURCHASE OF SECURITIES

The present financial analysis serves information purposes. It is intended to support institutional investors in making their own investment decisions; however in no way provide the investor with investment advice. Neither the author, nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be considered to be acting as an investment advisor or portfolio manager vis-à-vis an investor. Each investor must form his own independent opinion with regard to the suitability of an investment in view of his own investment objectives, experience, tax situation, financial position and other circumstances.

The financial analysis does not represent a recommendation or solicitation and is not an offer for the purchase of the security specified in this financial analysis. Consequently, neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall as a result be liable for losses incurred through direct or indirect employment or use of any kind whatsoever of information or statements arising out of this financial analysis.

A decision concerning an investment in securities should take place on the basis of independent investment analyses and procedures as well as other studies including, but not limited to, information memoranda, sales or issuing prospectuses and not on the basis of this document.

NO ESTABLISHMENT OF CONTRACTUAL OBLIGATIONS

By taking note of this financial analysis the recipient neither becomes a customer of First Berlin, nor does First Berlin incur any contractual, quasi-contractual or pre-contractual obligations and/or responsibilities toward the recipient. In particular no information contract shall be established between First Berlin and the recipient of this information.

NO OBLIGATION TO UPDATE

First Berlin, the author and/or the person responsible for passing on or distributing the financial analysis shall not be obliged to update the financial analysis. Investors must keep themselves informed about the current course of business and any changes in the current course of business of the analysed company.

DUPLICATION

Dispatch or duplication of this document is not permitted without the prior written consent of First Berlin.

SEVERABILITY

Should any provision of this disclaimer prove to be illegal, invalid or unenforceable under the respectively applicable law, then such provision shall be treated as if it were not an integral component of this disclaimer; in no way shall it affect the legality, validity or enforceability of the remaining provisions.

APPLICABLE LAW, PLACE OF JURISDICTION

The preparation of this financial analysis shall be subject to the law obtaining in the Federal Republic of Germany. The place of jurisdiction for any disputes shall be Berlin (Germany).

NOTICE OF DISCLAIMER

By taking note of this financial analysis the recipient confirms the binding nature of the above explanations.

By using this document or relying on it in any manner whatsoever the recipient accepts the above restrictions as binding for the recipient.

QUALIFIED INSTITUTIONAL INVESTORS

First Berlin financial analyses are intended exclusively for qualified institutional investors.

This report is not intended for distribution in the USA and/or Canada.